The UK and US have secured a important commercial pact that will keep no levies on British pharmaceutical products entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the National Health Service (NHS). This move secures that tariffs on these key goods will remain at nothing for a timeframe of the next three years.
This agreement is in response to earlier statements to significantly raise tariffs on patented pharmaceutical products, with increases floated as high as one hundred percent.
"This deal between the UK strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue equity to transatlantic pharmaceutical trade," a release noted.
Trade Impact
Pharmaceuticals constitute one of the the United Kingdom's largest exports to the US, which is easily the primary market for major companies like GSK and AstraZeneca.
Trade data indicate that in the year prior to the third quarter, the UK exported pharmaceutical products totaling billions to the US. This figure represented 17.4% of total UK exports in that period.
"This guarantee protects work, increases investment and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The deal entails several key changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to raise overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be restricted at 15%. Previously, rebates were more than twenty percent.
Industry Background
The deal comes amid a protracted dispute between the sector and the UK government over drug pricing and approval rates.
This friction were heightened by assertions that US patients were charged several times more for the same drugs than people in the Britain and the EU.
In recent months, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its total funding over the previous ten-year period.
